GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyeGene Inc (XKRX:185490) » Definitions » Net Issuance of Debt

EyeGene (XKRX:185490) Net Issuance of Debt : ₩0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is EyeGene Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. EyeGene's net issuance of debt for the three months ended in Dec. 2024 was ₩0 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Dec. 2024 was ₩0 Mil.

EyeGene Net Issuance of Debt Historical Data

The historical data trend for EyeGene's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyeGene Net Issuance of Debt Chart

EyeGene Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,286.82 -1,000.00 -2,950.36 -200.00 -

EyeGene Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

EyeGene Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EyeGene Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of EyeGene's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

EyeGene Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyeGene Inc (XKRX:185490) » Definitions » Net Issuance of Debt
Comparable Companies
XKRX:388870 XKRX:049960 XKRX:067370 XKRX:314130 XKRX:378800 XKRX:365270 XKRX:046210 XKRX:383930 XKRX:166480 XKRX:261780 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
Gangseo-gu, Seoul 401, B-dong 910 Gayang-dong, Seoul, KOR, 07528
Website
http://www.eyegene.co.kr
EyeGene Inc is a South Korea based bio-venture company. It researches and develops biopharmaceuticals. Its products include EG-Mirotin, EG-HPV, EGVac systems. It provides drugs for the treatment of age-related degenerative diseases. Its products target diabetic retinopathy.

EyeGene Headlines

No Headlines